1. Articles in category: Small Molecules

    1-24 of 27 1 2 »
    1. MYCN-targeting vaccines and immunotherapeutics.

      MYCN-targeting vaccines and immunotherapeutics.

      Hum Vaccin Immunother. 2016 Sep;12(9):2257-8

      Authors: Schramm A, Lode H

      Abstract Amplification and concomitant overexpression of the MYCN oncogene is a frequent event in many malignancies including the childhood tumors, neuroblastoma and medulloblastoma. MYCN is only expressed in a defined time frame during early developmental processes, (1) which is beneficial for approaches combatting tumor-specific MYCN.

      Read Full Article
      Mentions: MYCN
    2. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.

      Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.

      J Natl Cancer Inst. 2017 Nov 01;109(11):

      Authors: Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J

      Read Full Article
    3. Surface marker profiling of SH-SY5Y cells enables small molecule screens identifying BMP4 as a modulator of neuroblastoma differentiation.

      Surface marker profiling of SH-SY5Y cells enables small molecule screens identifying BMP4 as a modulator of neuroblastoma differentiation.

      Sci Rep. 2017 Oct 19;7(1):13612

      Authors: Ferlemann FC, Menon V, Condurat AL, Rößler J, Pruszak J

      Abstract Neuroblastoma is the most common extra-cranial solid tumor in children. Its broad spectrum of clinical outcomes reflects the underlying inherent cellular heterogeneity.

      Read Full Article
    4. p53 non-genotoxic activation and mTORC1 inhibition lead to effective combination for neuroblastoma therapy.

      p53 non-genotoxic activation and mTORC1 inhibition lead to effective combination for neuroblastoma therapy.

      Clin Cancer Res. 2017 Aug 18;:

      Authors: Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone KA, Schild L, Aviles-Padilla K, Nikzad R, Zhang Y, Chakraborty R, Molenaar JJ, Vasudevan S, Sheehan V, Kim ES, Paust S, Shohet JM, Barbieri E

      Read Full Article
    5. CHLA Researcher Awarded $1.9 Million by NIH to Study Novel Approach to Battling Neuroblastoma

      CHLA Researcher Awarded $1.9 Million by NIH to Study Novel Approach to Battling Neuroblastoma

      Muller Fabbri, MD, PhD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, has been awarded $1.9 million by the National Cancer Institute of the NIH to further his research on neuroblastoma.

      Read Full Article
    6. Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR 1/2/3/4 Mutations

      Conditions :   Advanced Malignant Solid Neoplasm;   FGFR1 Gene Mutation;   FGFR2 Gene Mutation;   FGFR3 Gene Mutation;   FGFR4 Gene Mutation;   Histiocytosis;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Stage III Childhood Non-Hodgkin Lymphoma;   Stage IV Childhood Non-Hodgkin Lymphoma Interventions :   Other: Laboratory Biomarker Analysis;   Drug: pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493;   Other: Pharmacological Study Sponsor :   National Cancer Institute (NCI) Not yet recruiting - verified June 2017

      Read Full Article
      Mentions: Refractory
    7. Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models.

      Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models.

      Transl Oncol. 2017 Jun 27;10(4):604-611

      Authors: Zhang L, Wu B, Baruchel S

      Abstract BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibitor crizotinib has proven to be effective in the treatment of ALK-mutated neuroblastoma, but crizotinib resistance was commonly observed in patients.

      Read Full Article
      Mentions: Treatment ALK
    8. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.

      Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.

      Pediatr Blood Cancer. 2017 May;64(5):

      Authors: Jiménez I, Baruchel A, Doz F, Schulte J

      Abstract The last few years have seen the identification of pharmacologic approaches to target bromodomain and extraterminal (BET) proteins for cancer treatment.

      Read Full Article
      Mentions: Treatment
    9. The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis.

      The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis.

      Cancer Lett. 2017 Jun 07;:

      Authors: Kollareddy M, Sherrard A, Park JH, Szemes M, Gallacher K, Melegh Z, Oltean S, Michaelis M, Cinatl J, Kaidi A, Malik K

      Read Full Article
      Mentions: ALK MYCN
    10. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.

      The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.

      Cancer Lett. 2017 Apr 25;:

      Authors: Lu J, Guan S, Zhao Y, Yu Y, Woodfield SE, Zhang H, Yang KL, Bieerkehazhi S, Qi L, Li X, Gu J, Xu X, Jin J, Muscal JA, Yang T, Xu GT, Yang J

      Read Full Article
      Mentions: ALK MYCN
    11. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

      Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

      Mol Oncol. 2017 Apr 22;:

      Authors: Tucker ER, Tall JR, Danielson LS, Gowan S, Jamin Y, Robinson SP, Banerji U, Chesler L

      Read Full Article
      Mentions: ALK
    12. Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

      Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

      Elife. 2017 Apr 20;6:

      Authors: Wang HQ, Halilovic E, Li X, Liang J, Cao Y, Rakiec DP, Ruddy DA, Jeay S, Wuerthner JU, Timple N, Kasibhatla S, Li N, Williams JA, Sellers WR, Huang A, Li F

      Read Full Article
      Mentions: ALK MYCN
    13. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

      PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

      Oncogene. 2017 Apr 10;:

      Authors: Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahún-Roncero M, Carbonari M, Ricci B, Heil C, Capalbo C, Belardinilli F, Coppa A, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G

      Read Full Article
      Mentions: MYCN
    14. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.

      P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.

      Int J Cancer. 2017 Mar 24;:

      Authors: Lopez-Barcons L, Maurer BJ, Kang MH, Reynolds CP

      Abstract We previously reported that concurrent ketoconazole, an oral anti-fungal agent and P450 enzyme inhibitor, increased plasma levels of the cytotoxic retinoid, fenretinide (4-HPR) in mice.

      Read Full Article
    15. A Phase I/II, Multicenter, OPEN-LABEL, DOSE-ESCALATION Study Of The Safety And Pharmacokinetics Ofcobimetinib In Pediatric And Young Adult Patients With Previously Treated Solid Tumors

      EudraCT Number: 2014-004685-25Sponsor Protocol Number: GO29665Sponsor Name: F. Hoffmann-La Roche LtdStart Date: 2016-04-28Medical condition: Solid TumorsDisease: Version: 19.0SOC Term: 100000004864Classification Code: 10065252Term: Solid tumorLevel: LLTPopulation Age: Children, Adolescents, Under 18, AdultsGender: Male, FemaleTrial Protocol: DE (Ongoing)

      Read Full Article
    16. Many Targeted Cancer Therapies Suppress T Cell Immune Responses

      PHILADELPHIA--(March 22, 2016)--In many cases, targeted therapies for cancer are preferred as treatments over chemotherapy and surgery because they attack and kill cancer cells with specific tumor-promoting mutations while sparing healthy, normal cells that do not express these mutations. In clinical trials, a heavy emphasis on the effects of targeted therapies on tumor cells has been explored, but the effects they have on the immune system have not been thoroughly investigated.

      Read Full Article
    17. Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.

      "However, the clonally acquired, oncogenic aberrations in relapsed neuroblastomas are currently being defined and may offer an opportunity to improve patient outcomes with molecularly targeted therapy directed toward aberrantly regulated pathways in relapsed disease. This review summarizes the current state of knowledge about neuroblastoma genetics and genomics, highlighting the improved prognostication and potential therapeutic opportunities that have arisen from recent advances in understanding germline predisposition, recurrent segmental chromosomal alterations, somatic point mutations and translocations, and clonal evolution in relapsed neuroblastoma."

      Read Full Article
      Mentions: MYCN Genetics
    18. PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.

      PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.

      Cancer Cell Int. 2015;15:91

      Authors: Qi L, Toyoda H, Xu DQ, Zhou Y, Sakurai N, Amano K, Kihira K, Hori H, Azuma E, Komada Y

      Abstract PURPOSE: AKT plays a pivotal role in the signal transduction of cancer cells. MK2206, an AKT inhibitor, has been shown to be an effective anti-cancer drug to a variety of cancer cell lines.

      Read Full Article
    19. PLK1 INHIBITION: PROSPECTIVE ROLE FOR THE TREATMENT OF PEDIATRIC TUMORS.

      PLK1 INHIBITION: PROSPECTIVE ROLE FOR THE TREATMENT OF PEDIATRIC TUMORS.

      Curr Drug Targets. 2015 Aug 25;

      Authors: Pezuk JA, Valera ET, Brassesco MS

      Abstract Over the years, polo-like kinase 1 (PLK1) has garnered great interest as a therapeutic target. The PLK1 is a member of a highly conserved serine/threonine kinase family that plays pivotal roles in mitosis, cytokinesis and DNA damage response in eukaryotic cells.

      Read Full Article
    1-24 of 27 1 2 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles